We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $5.98B
1-Year Est. Return 80.99%
This Fund
S&P 500
This Quarter Est. Return
+21.26%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.97B
AUM Growth
+$710M
Cap. Flow
+$33.6M
Cap. Flow %
0.68%
Top 10 Hldgs %
43.85%
Holding
701
New
35
Increased
130
Reduced
246
Closed
41

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$31M
2
BTI icon
British American Tobacco
BTI
+$29.2M
3
SAP icon
SAP
SAP
+$27.1M
4
HOOD icon
Robinhood
HOOD
+$17.9M
5
CLS icon
Celestica
CLS
+$13.7M

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$29.1M
2
TSM icon
TSMC
TSM
+$26.3M
3
META icon
Meta Platforms (Facebook)
META
+$23.5M
4
BEKE icon
KE Holdings
BEKE
+$22.1M
5
TCOM icon
Trip.com Group
TCOM
+$17M

Sector Composition

Rank Sector Weight
1 Technology 46.19%
2 Consumer Discretionary 14.25%
3 Communication Services 13.85%
4 Healthcare 7.17%
5 Consumer Staples 6.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
501
Syndax Pharmaceuticals
SNDX
$1.74B
$20.5K ﹤0.01%
2,186
– –
COGT icon
502
Cogent Biosciences
COGT
$6.95B
$20.3K ﹤0.01%
2,828
– –
PRAX icon
503
Praxis Precision Medicines
PRAX
$8.25B
$20.1K ﹤0.01%
477
– –
PGRE
504
DELISTED
Paramount Group
PGRE
$20.1K ﹤0.01%
3,287
+23
+0.7% +$120
AVXL icon
505
Anavex Life Sciences
AVXL
$238M
$20K ﹤0.01%
2,171
– –
RLJ icon
506
RLJ Lodging Trust
RLJ
$1.89B
$19.5K ﹤0.01%
2,676
-233
-8% -$1.68K
CRMD icon
507
CorMedix
CRMD
$577M
$19.1K ﹤0.01%
1,554
– –
AVBP icon
508
ArriVent BioPharma
AVBP
$1.4B
$18.8K ﹤0.01%
863
– –
ORIC icon
509
Oric Pharmaceuticals
ORIC
$1.23B
$18.3K ﹤0.01%
1,807
– –
REPL icon
510
Replimune Group
REPL
$449M
$18.3K ﹤0.01%
1,970
– –
CSR
511
Centerspace
CSR
$941M
$18.1K ﹤0.01%
301
-13
-4% -$797
XERS icon
512
Xeris Biopharma Holdings
XERS
$1.42B
$17.8K ﹤0.01%
3,817
– –
VIR icon
513
Vir Biotechnology
VIR
$1.49B
$17.8K ﹤0.01%
3,526
– –
QURE icon
514
uniQure
QURE
$2.52B
$17.4K ﹤0.01%
1,248
– –
ANAB icon
515
AnaptysBio
ANAB
$1.54B
$17.3K ﹤0.01%
779
– –
AAT
516
American Assets Trust
AAT
$1.48B
$17.2K ﹤0.01%
873
-42
-5% -$817
MLYS icon
517
Mineralys Therapeutics
MLYS
$2.38B
$17.2K ﹤0.01%
1,274
– –
PHAT icon
518
Phathom Pharmaceuticals
PHAT
$930M
$16.8K ﹤0.01%
1,751
– –
DAWN
519
DELISTED
Day One Biopharmaceuticals
DAWN
$16.8K ﹤0.01%
2,582
– –
TSCO icon
520
Tractor Supply
TSCO
$16.5B
$16.7K ﹤0.01%
317
-1,275
-80% -$65.2K
EYPT icon
521
EyePoint Inc
EYPT
$1B
$16.4K ﹤0.01%
1,747
– –
PDM
522
Piedmont Realty Trust
PDM
$1.2B
$16.2K ﹤0.01%
2,220
-107
-5% -$739
DEA
523
Easterly Government Properties
DEA
$1.17B
$16.1K ﹤0.01%
726
-34
-4% -$742
SANA icon
524
Sana Biotechnology
SANA
$916M
$15.6K ﹤0.01%
5,716
– –
STOK icon
525
Stoke Therapeutics
STOK
$1.83B
$15.4K ﹤0.01%
1,355
– –
19 20
21
22 23

Similar funds

CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
BP
BC Partners New York $5.96B AUM 15.21% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $5.94B AUM 18.44% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.03B AUM 40.55% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
AL
Appaloosa LP Short Hills, New Jersey $5.93B AUM 44.55% 1-Year Est. Return
CGPCS
Capital Group Private Client Services Los Angeles, California $5.93B AUM 27.73% 1-Year Est. Return

GF Fund Management's Q2 2025 Portfolio in Review

As of Q2 2025, GF Fund Management held 701 positions worth $4.97B, up 17% from $4.26B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

GF Fund Management's Q2 2025 filing shows 35 new, 130 increased, 246 reduced and 41 closed positions. Its largest new stake was Shopify: 120,000 shares worth $13.8M. The largest sale was NVIDIA, an estimated $29.1M.

By sector, the portfolio is most concentrated in Technology at 46% of assets, up from 42% a quarter earlier, followed by Consumer Discretionary and Communication Services.

  • GF Fund Management's largest Q2 2025 buy was Shopify: 120,000 shares worth $13.8M.
  • GF Fund Management added most to UnitedHealth in Q2 2025, an estimated $31M increase.
  • GF Fund Management's biggest Q2 2025 reduction was NVIDIA, cutting an estimated $29.1M.
  • GF Fund Management fully exited Salesforce in Q2 2025, selling an estimated $9.77M.
  • GF Fund Management's ten largest holdings make up 44% of its $4.97B portfolio in Q2 2025.
  • GF Fund Management opened 35 new positions and closed 41 in Q2 2025.
  • GF Fund Management's portfolio value rose 17% quarter-over-quarter to $4.97B.

Based on GF Fund Management's 13F filing for Q2 2025, filed 22 Jul 2025.